{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:01:54Z","timestamp":1789621314119,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Genet Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00438-026-02467-3","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:01:12Z","timestamp":1789614072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From scissors to editors: how the evolution of precision is redefining therapeutic genome editing"],"prefix":"10.1007","volume":"301","author":[{"given":"Mohadese","family":"Rahbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhane","family":"Lohrasbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8099-7984","authenticated-orcid":false,"given":"Amir","family":"Amiri-Yekta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"5","key":"2467_CR57","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/crispr.2020.0082","volume":"3","author":"F Baylis","year":"2020","unstructured":"Baylis F, Darnovsky M, Hasson K, Krahn TM (2020) Human Germline and Heritable Genome Editing: The Global Policy Landscape. CRISPR J 3(5):365\u2013377","journal-title":"CRISPR J"},{"issue":"1","key":"2467_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","volume":"431","author":"C Brokowski","year":"2019","unstructured":"Brokowski C, Adli M (2019) CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool. J Mol Biol 431(1):88\u2013101","journal-title":"J Mol Biol"},{"issue":"7","key":"2467_CR27","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.7150\/thno.71144","volume":"12","author":"YT Chan","year":"2022","unstructured":"Chan YT, Lu Y, Wu J, Zhang C, Tan HY, Bian ZX et al (2022) CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. Theranostics 12(7):3329\u20133344","journal-title":"Theranostics"},{"issue":"3","key":"2467_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/bfgp\/elaa001","volume":"19","author":"X Cheng","year":"2020","unstructured":"Cheng X, Fan S, Wen C, Du X (2020) CRISPR\/Cas9 for cancer treatment: technology, clinical applications and challenges. Brief Funct Genomics 19(3):209\u2013214","journal-title":"Brief Funct Genomics"},{"key":"2467_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","volume":"447","author":"M Chen","year":"2019","unstructured":"Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J (2019) CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett 447:48\u201355","journal-title":"Cancer Lett"},{"issue":"1","key":"2467_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJM200007063430107","volume":"343","author":"PJ Delves","year":"2000","unstructured":"Delves PJ, Roitt IM (2000) The immune system. N Engl J Med 343(1):37\u201349","journal-title":"N Engl J Med"},{"issue":"1","key":"2467_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri A, Herbst F, Fraietta JA (2022) Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer 21(1):78","journal-title":"Mol Cancer"},{"issue":"6","key":"2467_CR10","first-page":"100854","volume":"18","author":"Y Du","year":"2023","unstructured":"Du Y, Liu Y, Hu J, Peng X, Liu Z (2023) CRISPR\/Cas9 systems: Delivery technologies and biomedical applications. Asian J Pharm Sci 18(6):100854","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"2467_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/bmc-2021-0001","volume":"12","author":"JC Eissenberg","year":"2021","unstructured":"Eissenberg JC (2021) Our Image: The Ethics of CRISPR Genome Editing. Biomol concepts 12(1):1\u20137","journal-title":"Biomol concepts"},{"key":"2467_CR31","doi-asserted-by":"publisher","first-page":"834002","DOI":"10.3389\/fonc.2022.834002","volume":"12","author":"E Elmas","year":"2022","unstructured":"Elmas E, Saljoughian N, de Souza Fernandes Pereira M, Tullius BP, Sorathia K, Nakkula RJ et al (2022) CRISPR gene editing of human primary NK and T cells for cancer immunotherapy. Front Oncol 12:834002","journal-title":"Front Oncol"},{"issue":"7643","key":"2467_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM et al (2017) Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543(7643):113\u2013117","journal-title":"Nature"},{"issue":"5","key":"2467_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/1535-7163.MCT-17-0758","volume":"17","author":"N Floc\u2019h","year":"2018","unstructured":"Floc\u2019h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, M\u00e9nard L et al (2018) Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions. Mol Cancer Ther 17(5):885\u2013896","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2467_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.chom.2021.04.003","volume":"29","author":"CA Freije","year":"2021","unstructured":"Freije CA, Sabeti PC (2021) Detect and destroy: CRISPR-based technologies for the response against viruses. Cell Host Microbe 29(5):689\u2013703","journal-title":"Cell Host Microbe"},{"issue":"9","key":"2467_CR34","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1002\/cam4.2257","volume":"8","author":"Q Gao","year":"2019","unstructured":"Gao Q, Dong X, Xu Q, Zhu L, Wang F, Hou Y et al (2019) Therapeutic potential of CRISPR\/Cas9 gene editing in engineered T-cell therapy. Cancer Med 8(9):4254\u20134264","journal-title":"Cancer Med"},{"issue":"3","key":"2467_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11248-021-00247-w","volume":"30","author":"A Ghorbani","year":"2021","unstructured":"Ghorbani A, Hadifar S, Salari R, Izadpanah K, Burmistrz M, Afsharifar A et al (2021) A short overview of CRISPR-Cas technology and its application in viral disease control. Transgenic Res 30(3):221\u2013238","journal-title":"Transgenic Res"},{"issue":"8","key":"2467_CR54","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1134\/S0006297922080090","volume":"87","author":"I Gostimskaya","year":"2022","unstructured":"Gostimskaya I (2022) CRISPR\u2013Cas9: A history of its discovery and ethical considerations of its use in genome editing. Biochem (Moscow) 87(8):777\u2013788","journal-title":"Biochem (Moscow)"},{"issue":"12","key":"2467_CR14","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3390\/biom11121855","volume":"11","author":"C Guan","year":"2021","unstructured":"Guan C, Zhu X, Feng C (2021) DNA Nanodevice-Based Drug Delivery Systems. Biomolecules 11(12):1855","journal-title":"Biomolecules"},{"key":"2467_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jare.2021.11.018","volume":"40","author":"N Guo","year":"2022","unstructured":"Guo N, Liu JB, Li W, Ma YS, Fu D (2022) The power and the promise of CRISPR\/Cas9 genome editing for clinical application with gene therapy. J Adv Res 40:135\u2013152","journal-title":"J Adv Res"},{"issue":"1","key":"2467_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tvjl.2003.09.007","volume":"169","author":"JM Hammond","year":"2005","unstructured":"Hammond JM, Johnson MA (2005) Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics. Vet J 169(1):17\u201327","journal-title":"Vet J"},{"issue":"4","key":"2467_CR17","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1353\/pbm.2019.0046","volume":"62","author":"DM Hausman","year":"2019","unstructured":"Hausman DM (2019) What Is Cancer? Perspect Biol Med 62(4):778\u2013784","journal-title":"Perspect Biol Med"},{"key":"2467_CR48","unstructured":"https:\/\/crisprmedicinenews.com\/clinical-trials\/"},{"issue":"1","key":"2467_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s42003-023-05052-1","volume":"6","author":"G Jang","year":"2023","unstructured":"Jang G, Kweon J, Kim Y (2023) CRISPR prime editing for unconstrained correction of oncogenic KRAS variants. Commun Biology 6(1):681","journal-title":"Commun Biology"},{"issue":"1","key":"2467_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/cge.13589","volume":"97","author":"C Jiang","year":"2020","unstructured":"Jiang C, Meng L, Yang B, Luo X (2020) Application of CRISPR\/Cas9 gene editing technique in the study of cancer treatment. Clin Genet 97(1):73\u201388","journal-title":"Clin Genet"},{"issue":"11","key":"2467_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/molecules22111929","volume":"22","author":"D Kalafatovic","year":"2017","unstructured":"Kalafatovic D, Giralt E (2017) Cell-penetrating, peptides: design strategies beyond primary structure and amphipathicity. Molecules 22(11):1929","journal-title":"Molecules"},{"issue":"10","key":"2467_CR40","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1038\/s41596-019-0210-2","volume":"14","author":"MJ Kellner","year":"2019","unstructured":"Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F (2019) SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc 14(10):2986\u20133012","journal-title":"Nat Protoc"},{"issue":"20","key":"2467_CR13","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.3390\/ijms222010952","volume":"22","author":"M Kus-Li\u015bkiewicz","year":"2021","unstructured":"Kus-Li\u015bkiewicz M, Fickers P, Ben Tahar I (2021) Biocompatibility and Cytotoxicity of Gold Nanoparticles: Recent Advances in Methodologies and Regulations. Int J Mol Sci 22(20):10952","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2467_CR38","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3390\/ijms23031337","volume":"23","author":"MH Lee","year":"2022","unstructured":"Lee MH, Shin JI, Yang JW, Lee KH, Cha DH, Hong JB et al (2022) Genome editing using CRISPR-Cas9 and autoimmune diseases: a comprehensive review. Int J Mol Sci 23(3):1337","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2467_CR12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA (2018) Delivering CRISPR: a review of the challenges and approaches. Drug Delivery 25(1):1234\u20131257","journal-title":"Drug Delivery"},{"issue":"3","key":"2467_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","volume":"4","author":"W Liu","year":"2021","unstructured":"Liu W, Li L, Jiang J, Wu M, Lin P (2021) Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clin Med 4(3):179\u2013191","journal-title":"Precision Clin Med"},{"issue":"1","key":"2467_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12943-023-01738-6","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Shi M, Ren Y, Xu H, Weng S, Ning W et al (2023) Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol Cancer 22(1):35","journal-title":"Mol Cancer"},{"issue":"12","key":"2467_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.tibs.2018.09.010","volume":"43","author":"BR Madhanagopal","year":"2018","unstructured":"Madhanagopal BR, Zhang S, Demirel E, Wady H, Chandrasekaran AR (2018) DNA nanocarriers: programmed to deliver. Trends Biochem Sci 43(12):997\u20131013","journal-title":"Trends Biochem Sci"},{"key":"2467_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2018.06.002","volume":"32","author":"A Mahas","year":"2018","unstructured":"Mahas A, Mahfouz M (2018) Engineering virus resistance via CRISPR\u2013Cas systems. Curr Opin Virol 32:1\u20138","journal-title":"Curr Opin Virol"},{"key":"2467_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"64","author":"W Mehnert","year":"2012","unstructured":"Mehnert W, M\u00e4der K (2012) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 64:83\u2013101","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2467_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","volume":"109","author":"A Mehta","year":"2020","unstructured":"Mehta A, Merkel OM (2020) Immunogenicity of Cas9 Protein. J Pharm Sci 109(1):62\u201367","journal-title":"J Pharm Sci"},{"key":"2467_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s10439-012-0678-1","volume":"41","author":"AJ Mellott","year":"2013","unstructured":"Mellott AJ, Forrest ML, Detamore MS (2013) Physical non-viral gene delivery methods for tissue engineering. Ann Biomed Eng 41:446\u2013468","journal-title":"Ann Biomed Eng"},{"key":"2467_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-642-20718-1_2","volume":"12","author":"S Modrow","year":"2013","unstructured":"Modrow S, Falke D, Truyen U, Sch\u00e4tzl H (2013) Viruses: definition, structure, classification. Mol Virol 12:17\u201330. https:\/\/doi.org\/10.1007\/978-3-642-20718-1_2","journal-title":"Mol Virol"},{"issue":"35","key":"2467_CR36","doi-asserted-by":"publisher","first-page":"eaax0644","DOI":"10.1126\/sciimmunol.aax0644","volume":"4","author":"HF Moffett","year":"2019","unstructured":"Moffett HF, Harms CK, Fitzpatrick KS, Tooley MR, Boonyaratanakornkit J, Taylor JJ (2019) B cells engineered to express pathogen-specific antibodies protect against infection. Sci Immunol 4(35):eaax0644","journal-title":"Sci Immunol"},{"key":"2467_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00745-20","author":"I Mustafa Mujahed","year":"2021","unstructured":"Mustafa Mujahed I, Makhawi Abdelrafie M (2021) SHERLOCK and DETECTR: CRISPR-Cas systems as potential rapid diagnostic tools for emerging infectious diseases. J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.00745-20","journal-title":"J Clin Microbiol"},{"key":"2467_CR47","doi-asserted-by":"publisher","first-page":"112743","DOI":"10.1016\/j.biopha.2022.112743","volume":"148","author":"S Najafi","year":"2022","unstructured":"Najafi S, Tan SC, Aghamiri S, Raee P, Ebrahimi Z, Jahromi ZK et al (2022) Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections. Biomed Pharmacother 148:112743","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2467_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso 3rd","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR (2017) Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs Clin Immunotherapeutics Biopharmaceuticals Gene Therapy 31(4):317\u2013334","journal-title":"BioDrugs Clin Immunotherapeutics Biopharmaceuticals Gene Therapy"},{"issue":"2","key":"2467_CR55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","volume":"101","author":"KE Ormond","year":"2017","unstructured":"Ormond KE, Mortlock DP, Scholes DT, Bombard Y, Brody LC, Faucett WA et al (2017) Human germline genome editing. Am J Hum Genet 101(2):167\u2013176","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2467_CR22","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/curroncol30020152","volume":"30","author":"AA Rabaan","year":"2023","unstructured":"Rabaan AA, AlSaihati H, Bukhamsin R, Bakhrebah MA, Nassar MS, Alsaleh AA et al (2023) Application of CRISPR\/Cas9 Technology in Cancer Treatment: A Future Direction. Curr Oncol 30(2):1954\u20131976","journal-title":"Curr Oncol"},{"issue":"4","key":"2467_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/cancers14040947","volume":"14","author":"S Rafii","year":"2022","unstructured":"Rafii S, Tashkandi E, Bukhari N, Al-Shamsi HO (2022) Current status of CRISPR\/Cas9 application in clinical cancer research: opportunities and challenges. Cancers 14(4):947","journal-title":"Cancers"},{"issue":"17","key":"2467_CR25","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/0008-5472.CAN-21-2519","volume":"82","author":"S Sayed","year":"2022","unstructured":"Sayed S, Sidorova OA, Hennig A, Augsburg M, Cort\u00e9s Vesga CP, Abohawya M et al (2022) Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR-based editing. Cancer Res 82(17):3002\u20133015","journal-title":"Cancer Res"},{"issue":"2","key":"2467_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","volume":"29","author":"G Sharma","year":"2021","unstructured":"Sharma G, Sharma AR, Bhattacharya M, Lee SS, Chakraborty C (2021) CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Mol therapy: J Am Soc Gene Therapy 29(2):571\u2013586","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"key":"2467_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2091-5-10","volume":"5","author":"DP Tieleman","year":"2004","unstructured":"Tieleman DP (2004) The molecular basis of electroporation. BMC Biochem 5:1\u201312","journal-title":"BMC Biochem"},{"issue":"1","key":"2467_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.gt.3301105","volume":"7","author":"D Trono","year":"2000","unstructured":"Trono D (2000) Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 7(1):20\u201323","journal-title":"Gene Ther"},{"key":"2467_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/0-89603-328-7:3","volume":"55","author":"JC Weaver","year":"1995","unstructured":"Weaver JC (1995) Electroporation theory: concepts and mechanisms. Plant Cell Electroporation Electrofusion Protocols 55:3\u201328","journal-title":"Plant Cell Electroporation Electrofusion Protocols"},{"issue":"15","key":"2467_CR33","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.3390\/ijms241512317","volume":"24","author":"W Wei","year":"2023","unstructured":"Wei W, Chen ZN, Wang K (2023) CRISPR\/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. Int J Mol Sci 24(15):12317","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2467_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0889-8588(05)70004-6","volume":"12","author":"NA Wivel","year":"1998","unstructured":"Wivel NA, Wilson JM (1998) Methods of gene delivery. Hematol Oncol Clin N Am 12(3):483\u2013501","journal-title":"Hematol Oncol Clin N Am"},{"key":"2467_CR21","doi-asserted-by":"publisher","first-page":"113891","DOI":"10.1016\/j.addr.2021.113891","volume":"176","author":"X Xu","year":"2021","unstructured":"Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y et al (2021) Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment. Adv Drug Deliv Rev 176:113891","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2467_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41571-019-0166-8","volume":"16","author":"H Yin","year":"2019","unstructured":"Yin H, Xue W, Anderson DG (2019) CRISPR\u2013Cas: a tool for cancer research and therapeutics. Nat Reviews Clin Oncol 16(5):281\u2013295","journal-title":"Nat Reviews Clin Oncol"},{"key":"2467_CR41","doi-asserted-by":"publisher","first-page":"113541","DOI":"10.1016\/j.bios.2021.113541","volume":"193","author":"L Yin","year":"2021","unstructured":"Yin L, Man S, Ye S, Liu G, Ma L (2021) CRISPR-Cas based virus detection: Recent advances and perspectives. Biosens Bioelectron 193:113541","journal-title":"Biosens Bioelectron"},{"key":"2467_CR8","doi-asserted-by":"publisher","first-page":"114535","DOI":"10.1016\/j.addr.2022.114535","volume":"190","author":"N Yom-Tov","year":"2022","unstructured":"Yom-Tov N, Guy R, Offen D (2022) Extracellular vesicles over adeno-associated viruses: advantages and limitations as drug delivery platforms in precision medicine. Adv Drug Deliv Rev 190:114535","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"2467_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.copbio.2008.07.005","volume":"19","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Yu L-C (2008) Microinjection as a tool of mechanical delivery. Curr Opin Biotechnol 19(5):506\u2013510","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"2467_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virs.2022.01.017","volume":"37","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Hou W, Chen S (2022) Updates on CRISPR-based gene editing in HIV-1\/AIDS therapy. Virol Sin 37(1):1\u201310","journal-title":"Virol Sin"},{"issue":"1","key":"2467_CR49","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1038\/s41467-023-41829-y","volume":"14","author":"L Zhao","year":"2023","unstructured":"Zhao L, Koseki SRT, Silverstein RA, Amrani N, Peng C, Kramme C et al (2023) PAM-flexible genome editing with an engineered chimeric Cas9. Nat Commun 14(1):6175","journal-title":"Nat Commun"}],"container-title":["Molecular Genetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-026-02467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00438-026-02467-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-026-02467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:02:42Z","timestamp":1789617762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00438-026-02467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2467"],"URL":"https:\/\/doi.org\/10.1007\/s00438-026-02467-3","relation":{},"ISSN":["1617-4615","1617-4623"],"issn-type":[{"value":"1617-4615","type":"print"},{"value":"1617-4623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative literature review and does not involve any studies with human participants or animals performed by any of the authors. The authors adhered to ethical publishing standards, ensuring accurate citation and representation of all referenced works.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"193"}}